A survey of techniques for refrigeration, reliquefaction, and production of slush for hydrogen

Several techniques were surveyed for the refrigeration, reliquefaction and production of slush from hydrogen. The techniques included auger; bubbling helium gas; Simon desorption; the Petlier effect; Joule-Kelvin expansion using Stirling, Brayton, and Viulleumirer approaches; rotary reciprocating; a dilution refrigerator; adiabatic demagnetization of a paramagnetic salt; and adiabatic magnetization of a superconductor

The magnitude of the magnetic field near the surface of a high-T(sub c) superconductor with a trapped flux

In 1986, much excitement was caused by the discovery of a class of materials that conducted electricity with zero resistance at temperatures above the boiling temperature of liquid nitrogen. This excitement was checked by the difficulties of manufacturing ceramics and the usefulness of high temperature superconductors that were restricted by their becoming high resistive conductors at small current densities. A lack of pinning of the magnetic field flux caused the return of high resistance as the current was increased in these materials. A study of the magnetic field near the surface of a high temperature superconductor is the first step in the search for a means of pinning the flux lines and increasing their critical current densities. The author found that a comparison between the defects in the surface of the superconductor and the magnetic field showed only a change in the field near the notch and the edge. No correlation was found between the surface grain or structure and the oscillations in the magnetic field. The observed changes in the magnetic field show resonances which may give an indication of the non-flux pinning in these superconductors. A flux pinning mechanism will increase the critical current densities; therefore, other methods of determining this field should be tried. The author proposes using a flux gate magnetometer with a detector wound on a ferrite core to measure the magnitude and direction of the magnetic field

Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.001 for noninferiority) but was not superior to placebo with respect to efficacy (P=0.06 for superiority). The rates of death from cardiovascular causes, fatal or nonfatal myocardial infarction, fatal or nonfatal stroke, hospitalization for heart failure, and hospitalization for acute coronary syndrome, and the incidence of acute pancreatitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between the two groups. CONCLUSIONS: Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received exenatide and those who received placebo